Aldosterone

Aldosterone

SCHEMBL14373307

C[C@]12CCC(=O)C=C1CCC1C2[C@@H](O)C[C@@]2(C=O)C1CC[C@@H]2C(=O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 7/20 1.00
SHBG P04278 4/20 1.00
SERPINA6 P08185 4/20 1.00
PRKAA2 P54646 1/20 1.00
SMN1; SMN2 Q16637 6/20 0.77
HIF1A Q16665 6/20 0.77
LMNA P02545 4/20 0.77
HSD17B10 Q99714 4/20 0.77
MAPT P10636 3/20 0.77
CYP3A4 P08684 3/20 0.77
NFKB1 P19838 2/20 0.77
MAPK1 P28482 2/20 0.77
BLM P54132 1/20 0.77
CYP2C9 P11712 1/20 0.77
TSHR P16473 1/20 0.77
SLC22A2 O15244 1/20 0.77
SLC22A1 O15245 1/20 0.77
SLC22A3 O75751 1/20 0.77
THPO P40225 1/20 0.77
MTOR P42345 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aldosterone SCHEMBL15935548 1.00 NR3C2 (1.00) NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2
Aldosterone SCHEMBL19327156 1.00 NR3C2 (1.00) NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2
Aldosterone SCHEMBL7191919 1.00 NR3C2 (1.00) NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2
Aldosterone SCHEMBL21950215 1.00 NR3C2 (1.00) NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2
Aldosterone SCHEMBL600774 1.00 NR3C2 (1.00) NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2
Aldosterone SCHEMBL1675 1.00 NR3C2 (1.00) NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2
Aldosterone SCHEMBL21267959 0.99 NR3C2 (0.98) NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2
Aldosterone SCHEMBL21082811 0.99 NR3C2 (0.98) NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2
Aldosterone SCHEMBL27949081 0.99 NR3C2 (0.98) NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2
Aldosterone SCHEMBL7992710 0.97 NR3C2 (0.94) NR3C2SHBGSERPINA6PRKAA2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394290-B2 Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases UNIVERSITAET DES SAARLANDES CAMPUS SAARBRUECKEN (DE) 2016-07-19 US disclosed
US-20140155407-A1 SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES UNIVERSITAET DES SAARLANDES (DE) 2014-06-05 US disclosed
US-20070249571-A1 Novel conjugate compounds and dermatological compositions thereof TAMARKIN PHARMACEUTICALS (IL) 2007-10-25 US disclosed
US-20070249571-A1 Novel conjugate compounds and dermatological compositions thereof TAMARKIN PHARMACEUTICALS (IL) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249571-A1 Novel conjugate compounds and dermatological compositions thereof CYP24A1, VDR, CYP2R1 NR3C2 165/4885SHBG 21/4885SERPINA6 132/4885
US-20140155407-A1 SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES HSD11B1, CYP11B1, HSD11B2 NR3C2 16/4885SHBG 59/4885SERPINA6 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.